Abstract
Background After the prolonged COVID–19 pandemic, during which the seasonal influenza epidemic was suppressed, Japan experienced a record–breaking influenza A/H1N1 outbreak in the 2024/2025 season. This situation also raises a concern about the immunogenicity of the annual quadrivalent inactivated influenza vaccine (QIIV). This study evaluated post-vaccination hemagglutination inhibition (HI) antibody titers and their association with influenza infection risk among healthcare workers. Methods A serosurvey was conducted among staff at a national medical and research center in Tokyo in December 2024, one month after staff received the QIIV. HI antibody titers against vaccine strains were measured, and participants were followed for influenza infection until January 2025. Seroprotection was defined as an HI titer ≥40. A Cox proportional hazards model assessed the association between HI titers and infection risk among vaccinated participants. Results Among 1,507 vaccinated participants, only 12.7% had seroprotective HI titers against A/H1N1. Around 90% had no influenza history for at least four seasons and had received repeated vaccinations over two seasons. Participants with HI titers <40 had a 4–fold higher infection risk than those with titers ≥40. A dose–response association was observed, even within the range below the titer of 40. Relative to titers <10, titers of 10 and 20 conferred 47.3% and 57.9% protection, respectively. Conclusions After a prolonged period without a major influenza epidemic, HI titers against A/H1N1 were extremely low in vaccinated healthcare workers. Nonetheless, higher post–vaccination HI titers, even at relatively low levels, were associated with protection, supporting the benefit of vaccines.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by the NCGM COVID-19 Gift Fund (grant number 19K059 to TM), Japan Health Research Promotion Bureau Research Fund (grant number 2020-B-09 and 2024-B-01 to TM), and National Center for Global Health and Medicine (grant number 21A2013D and 23A2020D to TM, and grant number 24A1011 to SY).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was approved by the Ethics Committee of the National Center for Global Health and Medicine, Japan (approved number: NCGM-G-003598).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
We added a reference to the previously insufficient sections and corrected the company name of the vaccine provider.
Data Availability
All data produced in the present study are available upon reasonable request to the authors.
